Insights

Gathering insights about Esper…

Similar companies to Esper

Esper Tech Stack

Esper uses 8 technology products and services including Cloudflare, Segment, Google, and more. Explore Esper's tech stack below.

Cloudflare
Content Management System
Segment
Customer Data Platforms
Google
Miscellaneous
PDF.js
Miscellaneous
Open Graph
Miscellaneous
HSTS
Security
Google Tag Manager
Tag Management
ZURB Foundation
UI Frameworks

Media & News

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –
Dec 18, 2024 | www.globenewswire.com
Esperion Announces $210 Million Convertible Debt Financing
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain holders of its outstanding 4.00% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”). Pursuant to the Agreements, Esperion will issue $100 million aggregate principal amount of its 5.75% Convertible Senior Subordinated Notes due 2030 (the “New Notes”) consisting of (a) approximately $57.5 million principal amount of New Notes, along with approximately $153.4 million in cash, issued in exchange for approximately $210.1 million principal amount of the 2025 Notes (the “Exchange Transactions”) and (b) approximately $42.5 million principal amount of New Notes for cash (the “Subscription Transactions”), in each case, pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”).
Dec 13, 2024 | www.globenewswire.com
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing Pharmaceutical Products for More Than 80 Years – ANN ARBOR, Mich., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel.
Dec 12, 2024 | www.globenewswire.com
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance.
Dec 08, 2024 | seekingalpha.com
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.
Dec 03, 2024 | www.zacks.com
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
Nov 18, 2024 | www.globenewswire.com
Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence.
Nov 13, 2024 | seekingalpha.com

Esper's Email Address Formats

Esper uses at least 1 format(s):

Esper Email Formats	Example	Percentage
First.Last@esper.com	John.Doe@esper.com	32%
FLast@esper.com	JDoe@esper.com	18%
First@esper.com	John@esper.com	18%
First.Last@esper.com	John.Doe@esper.com	32%

Frequently Asked Questions

Where is Esper's headquarters located?

Esper's main headquarters is located at 1006 W 31st St Austin, Texas 78705 US. The company has employees across 5 continents, including North AmericaAfricaAsia.

What is Esper's stock symbol?

Esper is a publicly traded company; the company's stock symbol is ESPR.

What is Esper's official website and social media links?

Esper's official website is esper.com and has social profiles on LinkedIn.

How much revenue does Esper generate?

As of October 2024, Esper's annual revenue reached $1.8M.

What is Esper's NAICS code?

Esper's NAICS code is 5112 - Software Publishers.

How many employees does Esper have currently?

As of October 2024, Esper has approximately 42 employees across 5 continents, including North AmericaAfricaAsia. Key team members include Vice President Operations: V. C.Head Of Growth: J. E.Co-Founder & Ceo: M. M.. Explore Esper's employee directory with LeadIQ.

What industry does Esper belong to?

Esper operates in the Software Development industry.

What technology does Esper use?

Esper's tech stack includes CloudflareSegmentGooglePDF.jsOpen GraphHSTSGoogle Tag ManagerZURB Foundation.

What is Esper's email format?

Esper's email format typically follows the pattern of . Find more Esper email formats with LeadIQ.

How much funding has Esper raised to date?

As of October 2024, Esper has raised $8M in funding. The last funding round occurred on Aug 11, 2021 for $8M.

When was Esper founded?

Esper was founded in 2018.

Esper

Software DevelopmentTexas, United States11-50 Employees

Esper is empowering a new era of public administration with a platform that helps government evaluate and manage public policy. We partner with government to integrate and transform their data into actionable insights for more transparent, data-driven decision making.

Company Overview

Headquarters: 1006 W 31st St Austin, Texas 78705 US
Website: esper.com
Stock Symbol: ESPR
NAICS Code: 5112 - Software Publishers
Founded: 2018
Employees: 11-50

Media & News

Funding & Financials

$8M
Esper has raised a total of $8M of funding over 5 rounds. Their latest funding round was raised on Aug 11, 2021 in the amount of $8M.
$10M
Esper's revenue is in the range of $10M

Funding & Financials

$8M
Esper has raised a total of $8M of funding over 5 rounds. Their latest funding round was raised on Aug 11, 2021 in the amount of $8M.
$10M
Esper's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Esper

MobileIron

Metalogix

ManageEngine

Aurea

BlackBerry

Tanium

Ivanti

Pulse Secure

Citrix

VMware

AirWatch

ESET

OneTrust

Esper Tech Stack

Media & News

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Esperion Announces $210 Million Convertible Debt Financing

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Esper's Email Address Formats

Frequently Asked Questions

Where is Esper's headquarters located?

What is Esper's stock symbol?

What is Esper's official website and social media links?

How much revenue does Esper generate?

What is Esper's NAICS code?

How many employees does Esper have currently?

What industry does Esper belong to?

What technology does Esper use?

What is Esper's email format?

How much funding has Esper raised to date?

When was Esper founded?

Esper

Company Overview

Media & News

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Esperion Announces $210 Million Convertible Debt Financing

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?